Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572997 | 0.76 | CNR2 (0.52) | CNR2P2RX7PTGER2PTGER3POLB | |
| SCHEMBL2572998 | 0.76 | CNR2 (0.52) | CNR2P2RX7PTGER2PTGER3POLB | |
| SCHEMBL16238288 | 0.74 | CNR2 (0.60) | CNR2P2RX7PTGER2PTGER3PTGDR | |
| SCHEMBL9109062 | 0.70 | CNR2 (0.53) | CNR2P2RX7PTGER2PTGER3POLB | |
| SCHEMBL9109050 | 0.70 | CNR2 (0.53) | CNR2P2RX7PTGER2PTGER3POLB | |
| SCHEMBL9237546 | 0.69 | TDP1 (0.41) | CNR2HDAC6CNR1 | |
| SCHEMBL3713140 | 0.69 | CNR2 (0.53) | CNR2P2RX7POLB | |
| SCHEMBL3713136 | 0.69 | CNR2 (0.53) | CNR2P2RX7POLB | |
| SCHEMBL9288212 | 0.69 | CNR2 (0.56) | CNR2P2RX7CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL13285262 | 0.68 | PHGDH (0.43) | CNR2P2RX7PTGER2PTGER3CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885P2RX7 26/4885PTGER2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.